You are here

RSV

Where competition is heating up in pharma

Pharma Voice

Fri, 05/24/24 - 11:06 am

ulcerative colitis

Moderna Therapeutics

FDA delays decision on Moderna's RSV shot until the end of May

Fierce Biotech

Fri, 05/10/24 - 11:44 am

Moderna Therapeutics

Moderna quarterly sales beat expectations

Reuters

Thu, 05/2/24 - 11:28 am

Moderna Therapeutics

GSK's Arexvy maintains its RSV market dominance, looks to key label expansion as Moderna's mRNA threat looms

Fierce Pharma

Wed, 05/1/24 - 11:07 pm

Pfizer Eyes Broader Label for RSV Vaccine Abrysvo After Promising Phase III Data

BioSpace

Tue, 04/9/24 - 11:18 am

clinical trials

Blue Lake Biotechnology shares positive data from RSV vaccine trial

Clinical Trials Arena

Fri, 03/22/24 - 09:29 am

Blue Lake Biotechnology

RSV monoclonal Beyfortus was 90% effective at preventing hospitalizations in children this winter

Stat

Thu, 03/7/24 - 05:35 pm

monoclonal antibodies

RSV vaccines may be linked to small increased risk of developing Guillain-Barré syndrome, data suggest

Stat

Thu, 02/29/24 - 07:01 pm

Guillain-Barré Syndrome

Pfizer's Abrysvo maintains strong efficacy through 2nd RSV season, study finds

Fierce Pharma

Thu, 02/29/24 - 09:43 am

Moderna posts surprise quarterly profit as it eyes RSV vaccine approval

Medical Marketing and Media

Thu, 02/22/24 - 11:49 am

Moderna Therapeutics

Moderna shares slide as longer-term data shows quick fall in RSV vaccine efficacy

Reuters

Fri, 02/9/24 - 11:13 am

Moderna Therapeutics

clinical trials

Veru needs additional cash for fresh trial of respiratory distress drug

Fierce Biotech

Thu, 02/8/24 - 11:09 am

respiratory distress

GSK reports positive news on trio of high-profile products

Medical Marketing and Media

Wed, 02/7/24 - 09:13 pm

GSK’s Arexvy Leads Over Pfizer’s Abrysvo in Year One of RSV Vaccine Market Battle

Xtalks

Mon, 02/5/24 - 11:12 pm

Sanofi expects RSV antibody to ⁠breach blockbuster status in 2024, even as supply hitch drags on

Fierce Pharma

Thu, 02/1/24 - 11:33 am

GSK confirms Arexvy is a blockbuster but says the RSV battle has just begun

Fierce Pharma

Wed, 01/31/24 - 11:49 am

GSK RSV vaccine achieves blockbuster status in just over six months

Tip Ranks

Mon, 01/29/24 - 10:30 pm

AZ, Sanofi’s Beyfortus cleared in China for RSV prevention

Pharmaphorum

Tue, 01/2/24 - 10:09 am

AstraZeneca, Sanofi to supply 230,000 more RSV infant shots to US market

Reuters

Thu, 12/14/23 - 10:48 pm

AstraZeneca Buys into RSV Vaccine Market with Potential $1.1B Icosavax Purchase

BioSpace

Tue, 12/12/23 - 11:17 am

Pages